Serum PCSK9 and MYLIP/IDOL Levels in Familial Hypercholesterolemia: Relationship with Lipid Profile
Background: Familial Hypercholesterolemia (FH), which is defined as a genetic disorder that causes a person to have high levels of LDL-C for their entire life, and therefore increases the risk of heart disease. Both PCSK9 and MYLIP/IDOL are proteins involved in regulating the amount of LDL receptors present on cell surfaces, but use different mechanisms. Objective: To compare the levels of serum PCSK9 and MYLIP/IDOL along with other lipid-profile parameters between healthy individuals, untreated FH patients, and treated FH patients. Methods: A cross-sectional study comparing three groups of individuals with different types of hypercholesterolemia was conducted among 90 subjects from Baghdad, Iraq (age 20-50 years): 30 normal control group members; 30 untreated familial hypercholesterolemia (FH) patients; and 30 treated FH patients. The serum PCSK9 and MYLIP/IDOL levels were determined via sandwich ELISA, while the concentrations of TC, TG, HDL-C, and LDL-C were evaluated through the use of a Roche Cobas Integra 400 analyzer. Results: There were differences among groups in all parameters measured (P<0.0001). The untreated FH group exhibited higher TC, TG, LDL-C, PCSK9, and MYLIP/IDOL than the control group; however, the untreated FH group also exhibited lower HDL-C than the control group. When compared to the untreated FH group, the treated FH group exhibited lower TC, LDL-C, and MYLIP/IDOL; conversely, the treated FH group also exhibited higher HDL-C and PCSK9 than the untreated FH group. After multiplicity adjustment, there were no differences between groups in terms of TG. The untreated FH group exhibited a positive correlation between MYLIP/IDOL and TC (r=0.607; adjusted P=0.0034). ROC analyses demonstrated that the highest area under curves (AUCs) were observed for LDL-C (1.000), TC (0.983), MYLIP/IDOL (0.982), and PCSK9 (0.921). Conclusion: There were significant lipid alterations in FH patients, which were accompanied by differences in PCSK9 and MYLIP/IDOL levels. Although treated FH patients had higher PCSK9 levels than untreated FH patients, their MYLIP/IDOL levels were lower. This may reflect different regulatory mechanisms for the LDL receptor pathway after treatment.
Authors
- Ghufran Saad Nsaif
Institutions
- University of Baghdad (IQ)
Publication Details
- Journal
- NIU Journal of Health Sciences
- Published
- 2026-11-16
- DOI
- https://doi.org/10.58709/niujhs.v12i3.2776
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00